Nutritional recommendations for patients with non-alcoholic fatty liver disease: An evidence based review

Practical Gastroenterology

Volumn 34, Issue 2, 2010, Pages 8-16

  Naniwadekar, Ashutosh S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETAINE; HIGH FRUCTOSE CORN SYRUP; OMEGA 3 FATTY ACID; PLACEBO; SELENIUM; SWEETENING AGENT; TETRAHYDROLIPSTATIN; TRANS FATTY ACID; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANTIOXIDANT ACTIVITY; ARTICLE; BARIATRIC SURGERY; CALORIC RESTRICTION; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; EXERCISE; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIVER BIOPSY; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRITIONAL REQUIREMENT; PATHOGENESIS; WEIGHT REDUCTION;

EID: 77953522864     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Matteoni CA, Younossi ZM, Gramlich T, et al: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.
2. Clark JM: The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40(Suppl 1):S5-10
3. Maheshwari A, Thuluvath PJ: Cryptogenic cirrhosis and NAFLD: are they related? Am J Gastroenterol 2006;101:664-8.
4. Marchesini G, Bugianesi E, Forlani G, et al: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
5. Brunt EM: Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21:3-16.
6. Clark JM, Brancati FL, Diehl AM: Nonalcoholic fatty liver disease: the most common cause of abnormal liver enzymes in the U.S. population. Gastroenterology 2001;120(suppl 1):A65.
7. Clark JM, Brancati FL, Diehl AM: Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-1657.
8. Mofrad P, Contos MJ, Haque M: Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-1292.
9. Bellentani S, Saccoccio G, Masutti F, et al: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112-117.
10. Browning JD, Szczepaniak LS, Dobbins R et al: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395.
11. Adams LA, Lymp JF, St Sauver J et al: The natural history of non-alcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.
12. Cusi, K: Role of Insulin Resistance and Lipotoxicity in Non- Alcoholic Steatohepatitis. Clin Liver Dis 2009;13:545-563.
13. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99(5):1408-13.
14. Ueno T, Sugawara H, Sujaku K, et al: Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27(1):103-7.
15. Kugelmas M, Hill DB, Vivian B, et al: Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003;38:413-9.
16. Schafer S, Kantartzis K, Machann J, et al: Lifestyle intervention in individuals with normal versus impaired glucose tolerance. Eur J Clin Invest 2007;37(7):535-43.
17. Hickman IJ, Jonsson JR, Prins JB, et al: Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53(3):413-9.
18. Vajro P, Mandato C, Franzese A, et al: Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr 2004;38(1):48-55.
19. Huang MA, Greenson JK, Chao C, et al: One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005;100(5):1072-81.
20. Nobili V, Manco M, Devito R, et al: Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48(1): 119-28.
21. Samaha FF, Iqbal N, Seshadri P, et al: A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 2003;348:2074-2081.
22. Stern L, Iqbal N, Seshadri P, et al: The effects of low carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med 2004;140:778-785.
23. Dansinger ML, Gleason JA, Griffith JL, et al: Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005;293:43-53.
24. Andersen T, Gluud C, Franzmann MB, et al: Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12:224-9.
25. Harrison SA, Fincke C, Helinski D, et al: A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004;20:623-628.
26. Hatzitolios A, Savopoulos C, Lazaraki G, et al: Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004;23(4):131-134.
27. Sabuncu T, Nazligul Y, Karaoglanoglu M, et al: The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 2003;12:189-192.
28. Zelber-Sagi S, Kessler A, Brazowsky E, et al: A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4(5):639-4
29. Rucker D, Padwal R, Li SK, et al: Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335(7631):1194-9.
30. Lirussi F, Azzalini L, Orando S, et al: Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007;1: CD004996.
31. Abdelmalek M, Schuyler O, Angulo P, et al: Betaine for Nonalcoholic Fatty Liver Disease: Results of a Randomized Placebo-Controlled Trial. Hepatology 2009; Epub
32. Reddy JK: Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2001;281(6): G1333-9.
33. Capanni M, Calella F, Biagini MR, et al: Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006;23:1143-1151.
34. Zhu FS, Liu S, Chen XM, et al: Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008; 14:6395-6400.
35. Spadaro L, Magliocco O, Spampinato D, et al: Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008;40:194-199.
36. Andrea J. Cussons, Gerald F. Watts, Trevor A. Mori, et al: Omega-3 Fatty Acid Supplementation Decreases Liver Fat Con-tent in Polycystic Ovary Syndrome: A Randomized Controlled Trial Employing Proton Magnetic Resonance Spectroscopy. J Clin Endocrinol Metab 2009;94(10):3842-3848.
37. Porikos KP, Van Itallie TB: Diet induced changes in serum transaminases and triglyceride levels in healthy men. Role of sucrose and excess calories. Am J Med 1983;75:624-630.
38. Havel PJ: Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr Rev 2005;63:133-157.
39. Ouyang X, Cirillo P, Sautin Y, et al: Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008;48(6):993-9.
40. Le K, Ith M, Kreis R, et al: Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr 2009;89:1760-5.
41. Zaloga GP, Harvey KA, Stillwell W: Trans fatty acids and coronary heart disease. Nutr Clin Pract. 2006, 21(5): 505-12.
42. Tetri LH, Basaranoglu M, Brunt EM, et al: Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008; 295:G987-G995.
43. Koppe SWP, Elias M, Moseley RH, Green RM. Trans fat feeding results in higher serum alanine aminotransferase and increased insulin resistance compared with a standard murine high-fat diet. Am J Physiol Gastrointest Liver Physiol 2009; 297:G378-G384.
44. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med 1991;115(12):956-61.
45. Mummadi RR, Kasturi KS, Chennareddygari S, et al: Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008; 6(12):1396-402.
46. Adams TD, Gress RE, Smith SC, et al: Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357:753-61.
47. Brolin RE, Bradley LJ, Taliwal RV: Unsuspected cirrhosis discovered during elective obesity operations. Arch Surg 1998;133:84-8.
48. Kral JG, Thung SN, Biron S, et al: Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004;135:48-58.